Everolimus
About
Therapy type: Targeted therapy
Therapy strategy: PI3K/AKT/mTOR inhibition
Mappings
NCI Thesaurus: Everolimus (ncit:C48387)
RxNorm: everolimus (rxcui:141704, omop:4324761)
SNOMED: Everolimus (sctid:428698007, omop:19011440)
Therapeutic response
Precision oncology relationships for therapeutic response involving this therapy.
| Organization(s) | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| EMA (1) FDA (1) | ER positive, HER2-negative | Invasive Breast Carcinoma | Everolimus, Exemestane | |
| EMA (1) FDA (1) | HER2-negative, PR positive | Invasive Breast Carcinoma | Everolimus, Exemestane | |
| EMA (1) FDA (1) | ER positive, HER2-negative, PR positive | Invasive Breast Carcinoma | Everolimus, Exemestane | |
| FDA (1) | TSC1 oncogenic variants | Renal Angiomyolipoma | Everolimus | |
| FDA (1) | TSC2 oncogenic variants | Renal Angiomyolipoma | Everolimus | |
| FDA (1) | TSC1 oncogenic variants | Subependymal Giant Cell Astrocytoma | Everolimus | |
| FDA (1) | TSC2 oncogenic variants | Subependymal Giant Cell Astrocytoma | Everolimus |